Unknown

Dataset Information

0

EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma.


ABSTRACT: Surgery is the only curative treatment for early-stage non-small cell lung cancer (NSCLC) patients. However, approximately one-third of these patients develop recurrence, which remains the main cause of mortality in the postsurgical treatment of NSCLC. Many molecular markers have been proposed to predict recurrence of early-stage disease, but no marker has demonstrated sufficient reliability for clinical application. In the present study, the novel protein EF-hand domain-containing protein D2 (EFHD2) was identified as expressed in highly metastatic tumor cells. EFHD2 increased the formation of protrusive invadopodia structures and cell migration and invasion abilities and promoted the epithelial-to-mesenchymal transition (EMT) character of lung adenocarcinoma cells. We demonstrated that the mechanism of EFHD2 in enhancing EMT occurs partly through inhibition of caveolin-1 (CAV1) for cancer progression. The expression of EFHD2 was significantly correlated with postsurgical recurrence of patients with stage I lung adenocarcinoma in the Kaplan-Meier-plotter cancer database search and our retrospective cohort study (HR, 6.14; 95% CI, 2.40-15.74; P?

SUBMITTER: Fan CC 

PROVIDER: S-EPMC5668280 | biostudies-literature | 2017 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

EFHD2 promotes epithelial-to-mesenchymal transition and correlates with postsurgical recurrence of stage I lung adenocarcinoma.

Fan Chi-Chen CC   Cheng Wei-Chung WC   Huang Yu-Chuen YC   Sher Yuh-Pyng YP   Liou Nia-Jhen NJ   Chien Yu-Chuan YC   Lin Pei-Shan PS   Lin Pei-Syuan PS   Chen Chung-Hsuan CH   Chang Wei-Chao WC  

Scientific reports 20171106 1


Surgery is the only curative treatment for early-stage non-small cell lung cancer (NSCLC) patients. However, approximately one-third of these patients develop recurrence, which remains the main cause of mortality in the postsurgical treatment of NSCLC. Many molecular markers have been proposed to predict recurrence of early-stage disease, but no marker has demonstrated sufficient reliability for clinical application. In the present study, the novel protein EF-hand domain-containing protein D2 (E  ...[more]

Similar Datasets

| S-EPMC6398409 | biostudies-literature
| S-EPMC9295072 | biostudies-literature
| S-EPMC5787518 | biostudies-literature
| S-EPMC5601643 | biostudies-literature
| S-EPMC5542185 | biostudies-literature
| S-EPMC9308325 | biostudies-literature
| S-EPMC7419050 | biostudies-literature
| S-EPMC6767874 | biostudies-literature
| S-EPMC4818680 | biostudies-literature
| S-EPMC5834284 | biostudies-literature